[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reduced-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reduced-ejection-fraction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100607729","sacubitrilvalsartan-in-patients-with-prosthetic-heart-valves-with-heart-failure-and-reduced-ejection-fraction-100607729",false,"NCT07192341","Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Effect of Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with a history of prosthetic heart valves.\n* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Use of a circulatory auxiliary circulation device.\n* Severe hepatic \\[alanine aminotransferase (ALT) \\>120 U\u002FL\\] and renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\\].\n* Blood pressure \\\u003C100\u002F60 mmHg.\n* Serum potassium \\>5.3 mmol\u002FL.\n* Severe pulmonary hypertension.\n* Malignant arrhythmia.\n* Malignant tumor.\n* Known history of hereditary or primary angioedema.\n* Serious adverse drug reactions or serious complications over the course of treatment.","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effect of sacubitril\u002Fvalsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).",[26,27,28,29],"Sacubitril\u002FValsartan","Prosthetic Heart Valve","Heart Failure","Reduced Ejection Fraction","RECRUITING","2025-09-27",{"date":33,"type":34},"2025-09-30","ACTUAL",{"date":31,"type":34},{"date":37,"type":20},"2026-02-01",{"name":39,"class":40},"Kafrelsheikh University","OTHER"]